Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. Issue 3 (March 2015)
- Record Type:
- Journal Article
- Title:
- Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. Issue 3 (March 2015)
- Main Title:
- Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer
- Authors:
- Valentini, Vincenzo
van Stiphout, Ruud G.P.M.
Lammering, Guido
Gambacorta, Maria A.
Barba, Maria C.
Bebenek, Marek
Bonnetain, Franck
Bosset, Jean F.
Bujko, Krzysztof
Cionini, Luca
Gerard, Jean P.
Rödel, Claus
Sainato, Aldo
Sauer, Rolf
Minsky, Bruce D.
Collette, Laurence
Lambin, Philippe - Abstract:
- <abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st070">Abstract</title> <sec> <title id="st075">Purpose</title> <p id="sp0005">Personalized treatments based on predictions for patient outcome require early characterization of a rectal cancer patient's sensitivity to treatment. This study has two aims: (1) identify the main patterns of recurrence and response to the treatments (2) evaluate pathologic complete response (pCR) and two-year disease-free survival (2yDFS) for overall survival (OS) and their potential to be relevant intermediate endpoints to predict.</p> </sec> <sec> <title id="st080">Methods</title> <p id="sp0010">Pooled and treatment subgroup analyses were performed on five large European rectal cancer trials (2795 patients), who all received long-course radiotherapy with or without concomitant and/or adjuvant chemotherapy. The ratio of distant metastasis (DM) and local recurrence (LR) rates was used to identify patient characteristics that increase the risk of recurrences.</p> </sec> <sec> <title id="st085">Findings</title> <p id="sp0015">The DM/LR ratio decreased to a plateau in the first 2 years, revealing it to be a critical follow-up period. According to the patterns of recurrences, three patient groups were identified: 5–15% had pCR and were disease free after 2 years (excellent prognosis), 65–75% had no pCR but were disease free (good prognosis) and 15–30% had neither pCR nor 2yDFS (poor prognosis).</p> </sec> <sec> <title<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st070">Abstract</title> <sec> <title id="st075">Purpose</title> <p id="sp0005">Personalized treatments based on predictions for patient outcome require early characterization of a rectal cancer patient's sensitivity to treatment. This study has two aims: (1) identify the main patterns of recurrence and response to the treatments (2) evaluate pathologic complete response (pCR) and two-year disease-free survival (2yDFS) for overall survival (OS) and their potential to be relevant intermediate endpoints to predict.</p> </sec> <sec> <title id="st080">Methods</title> <p id="sp0010">Pooled and treatment subgroup analyses were performed on five large European rectal cancer trials (2795 patients), who all received long-course radiotherapy with or without concomitant and/or adjuvant chemotherapy. The ratio of distant metastasis (DM) and local recurrence (LR) rates was used to identify patient characteristics that increase the risk of recurrences.</p> </sec> <sec> <title id="st085">Findings</title> <p id="sp0015">The DM/LR ratio decreased to a plateau in the first 2 years, revealing it to be a critical follow-up period. According to the patterns of recurrences, three patient groups were identified: 5–15% had pCR and were disease free after 2 years (excellent prognosis), 65–75% had no pCR but were disease free (good prognosis) and 15–30% had neither pCR nor 2yDFS (poor prognosis).</p> </sec> <sec> <title id="st090">Interpretation</title> <p id="sp0020">Compared with pCR, 2yDFS is a stronger predictor of OS. To adapt treatment most efficiently, accurate prediction models should be developed for pCR to select patients for organ preservation and for 2yDFS to select patients for more intensified treatment strategies.</p> </sec> </abstract> … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 114:Issue 3(2015:Mar.)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 114:Issue 3(2015:Mar.)
- Issue Display:
- Volume 114, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 114
- Issue:
- 3
- Issue Sort Value:
- 2015-0114-0003-0000
- Page Start:
- 302
- Page End:
- 309
- Publication Date:
- 2015-03
- Subjects:
- Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2015.02.001 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3439.xml